Prothena Corp. Plc

How big is Prothena Corp. Plc?

As of Jun 18, Prothena Corp. Plc has a market capitalization of 306.81 million, with net sales of 137.93 million and a net profit of -110.27 million over the latest four quarters. The company reported shareholder's funds of 486.93 million and total assets of 547.11 million as of Dec 24.

Market Cap: As of Jun 18, Prothena Corp. Plc has a market capitalization of 306.81 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Prothena Corp. Plc reported net sales of 137.93 million and a net profit of -110.27 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 486.93 million and total assets of 547.11 million.

What does Prothena Corp. Plc do?

Prothena Corp. Plc is a biotechnology company focused on developing immunotherapies for diseases related to protein misfolding and cell adhesion. As of March 2025, it has a market cap of $306.81 million, with net sales of $3 million and a net loss of $60 million.

Overview: <BR>Prothena Corp. Plc is a global biotechnology company focused on the discovery, development, and commercialization of immunotherapies for diseases involving protein misfolding or cell adhesion, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -60 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 306.81 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.95 <BR>Return on Equity: -25.19% <BR>Price to Book: 0.70<BR><BR>Contact Details: <BR>Address: Dublin 1, 25-28 North Wall Quay, DUBLIN None : A96 T927 <BR>Tel: 353 1 2362500 <BR>Fax: 353 1 9023510 <BR>Website: http://www.prothena.com/

Who are in the management team of Prothena Corp. Plc?

As of March 2022, Prothena Corp. Plc's management team includes Dr. Lars Ekman (Independent Chairman), Dr. Gene Kinney (President and CEO), and several independent directors: Ms. Paula Cobb, Mr. Richard Collier, Mr. Shane Cooke, Dr. K. Anders Harfstrand, and Dr. Christopher Henney. The team features a blend of executive leadership and independent directors.

As of March 2022, the management team of Prothena Corp. Plc includes the following individuals:<BR><BR>- Dr. Lars Ekman, who serves as the Independent Chairman of the Board.<BR>- Dr. Gene Kinney, who is the President, Chief Executive Officer, and Director.<BR>- Ms. Paula Cobb, who is an Independent Director.<BR>- Mr. Richard Collier, who is also an Independent Director.<BR>- Mr. Shane Cooke, serving as an Independent Director.<BR>- Dr. K. Anders Harfstrand, who is an Independent Director.<BR>- Dr. Christopher Henney, who is an Independent Director.<BR><BR>In summary, the management team consists of a mix of independent directors and key executive leadership.

Should I buy, sell or hold Prothena Corp. Plc?

Is Prothena Corp. Plc overvalued or undervalued?

As of August 8, 2022, Prothena Corp. Plc is considered overvalued and risky due to a negative return on equity of -25.19%, a price to book value ratio of 0.67, and unfavorable comparisons to peers, indicating a cautious outlook on its financial health.

As of 8 August 2022, Prothena Corp. Plc's valuation grade changed from fair to risky, indicating a shift towards a more cautious outlook. The company is currently overvalued based on its financial metrics, particularly given its negative return on equity of -25.19% and a price to book value ratio of 0.67, which suggests that the market is pricing the stock higher than its underlying assets justify. Additionally, the EV to EBITDA ratio stands at 0.92, reflecting a concerning valuation relative to its earnings potential.<BR><BR>In comparison to its peers, Prothena's valuation appears unfavorable; for instance, its peer has a P/E ratio of -1.69 and an EV to EBITDA of -0.36, highlighting a stark contrast in financial health. The absence of positive earnings further complicates the valuation picture, reinforcing the notion that the stock is overvalued. Although specific return data is not available, the lack of positive returns compared to the S&P 500 likely supports the view that the stock is not performing favorably in the market.

Is Prothena Corp. Plc technically bullish or bearish?

As of October 3, 2025, Prothena Corp. Plc shows a mildly bullish trend overall, supported by mixed technical indicators, including a bullish monthly RSI and weekly MACD, but tempered by bearish daily moving averages.

As of 3 October 2025, the technical trend for Prothena Corp. Plc has changed from sideways to mildly bullish. The weekly MACD is mildly bullish, while the monthly MACD also supports this stance. The monthly RSI is bullish, contrasting with the bearish weekly RSI. The Bollinger Bands indicate a mildly bullish trend on the weekly chart but are mildly bearish on the monthly. The KST shows a bullish weekly trend but a bearish monthly trend, and the Dow Theory indicates a mildly bullish monthly trend with no trend on the weekly. The daily moving averages are mildly bearish, which tempers the overall bullish sentiment. Overall, the indicators suggest a mildly bullish stance, albeit with some mixed signals, particularly in the short term. Multi-period return data is not available for comparison with the S&P 500.